NIPT Menu and Technology Offerings
10
>10
45
Voice-of-Customer Research
Objective
A leading diagnostics player asked DeciBio to characterize the evolving NIPT market to help inform strategic positioning regarding menu offerings and technological approach
Our Approach
Secondary Research
- Gathered data around annual birth rates and average age of first-time mothers across ~10 ex-U.S. regions
- Reviewed product specifications of competing vendors to understand menu offerings, test prices and technological approaches
- Conducted clinical trial analysis of ~50 active trials related to NIPT to evaluate interest in testing for conditions beyond T21, T18, T13
Primary Research
- Conducted 11 in-depth stakeholder interviews with HCPs (OBGYNs and MFMs), lab directors, and industry KOLs in multiple settings across APAC, Europe and the Middle East
Outcome
Key takeaways from DeciBio’s presentation to the client team included:
- Bifurcation of testing is real and currently vendor-driven in NIPT
- Significant regional nuances exist, with high willingness-to-pay among certain segments of the market
- Client should consider broadening its menu offerings in order to remain competitive and continue to maintain its global position
Related Client Results
Clinical, Genomic, and Pathology Real-World Data (RWD) Market Landscape Assessment
Voice-of-Customer Research
Pricing Strategy
Competitive Analysis
Global Companion Diagnostic Guideline Mapping and Strategy
Biomarker and Diagnostics Strategy
Go-to-Market Strategy
RNA-based Oncology Biomarker Market Landscape
Voice-of-Customer Research
Competitive Analysis
Biomarker and Diagnostics Strategy
Product Specification Mapping
